Klarithran 500 Tablets, Klarithran Suspension 125 Mg/5 Ml, Klarithran Suspension 250Mg/5Ml 500 mg, 125 mg/5 ml, 250 mg/5 ml Tablets, Suspension
PDF Leaflet Revision Date: 14 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention and treatment of nausea and vomiting induced by cytostatic therapy and postoperative nausea and vomiting.
Dosage (summary)
Adults: 3 mg IV for cytostatic therapy; 1 mg IV for postoperative nausea.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy and lactation due to safety concerns.
Key Drug Interactions
- QT prolonging agents
- Serotonergic medications
Contraindications
- Hypersensitivity to granisetron
- Children under 2 years
- Congenital long QT syndrome
Common side effects
- Headache
- Constipation
- Dizziness
Counselling Points
- Administer prior to cytostatic therapy
- Monitor for signs of myocardial ischaemia
- Report any adverse reactions
Serious warnings
- May cause dysrhythmias
- Monitor for serotonin syndrome
- Risk of myocardial ischaemia
Important Disclaimer
The Klarithran 500 Tablets, Klarithran Suspension 125 Mg/5 Ml, Klarithran Suspension 250Mg/5Ml 500 mg, 125 mg/5 ml, 250 mg/5 ml Tablets, Suspension professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
